Middle East
GDN Online App available on
App Store / Play Store
Gulf Daily News Gulf Daily News
Gulf Daily News Gulf Daily News Gulf Daily News Gulf Daily News Gulf Daily News
Thursday, February 21, 2019 ARCHIVES  |  SEARCH  |  POST ADS  |  ADVERTISE  |  SUBSCRIBE   |  LOGIN   |  CONTACT US

UAE health authorities withdraw Leflocad 500mg tablets

GDN Online Desk

Abu Dhabi: The UAE health authorities have decided to withdraw Leflocad 500mg tablets LF217017 and LF217028 from the market, according to Al Bayan.

The Ministry of Health and Prevention announced the move, based on the voluntary decision by the manufacturing company Jubilant Life Sciences to withdraw Leflocad tablets.

The inadequate use of inactive ingredient Crospovidone was behind the decision to withdraw the tablets.

The Abu Dhabi Health Directorate asked the agent to withdraw the tablets and urged pharmacies to stop selling the medication, return the remaining stocks and report any side-effects.

Leflocad 500mg is used for bacterial disease affecting the skin and lungs, bacterial infections, skin infections, soft tissue infections, plague and other conditions.

You Might Like